AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Compass Therapeutics, Inc. Director's Dealing 2020

Aug 11, 2020

32588_dirs_2020-08-10_d47f4d7c-c767-4a11-90a8-468bed301fe0.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Compass Therapeutics, Inc. (NONE)
CIK: 0001738021
Period of Report: 2020-08-06

Reporting Person: SQUINTO STEPHEN P (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-08-06	Stock Option (Right to Buy)	$5.00	A	30000	Acquired	2030-08-06	Common Stock (30000)	Direct

Footnotes

F1: 50% of this option is immediately vested and exercisable, with the remainder vesting in 24 substantially equal monthly installments thereafter.